Work

IUC24420-77 Prognostic impact of ABCA1/ABCG1 expression, lipid parameters, and nephrectomy in patients with renal cell carcinoma receiving immune checkpoint inhibitors

Year: 2025

Type: article

Abstract: Background Despite advances with immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma (mRCC), many patients do not achieve durable responses. The CHOMET study aimed to evaluate prognostic factors in patients receiving first-line ICIs, focusing on tumor expression of cholesterol transporters (ABCA1/ABCG1), lipid and nutritional status, and the role of nephrectomy. Methods CHOMET was a single-center retrospective study of patients with mRCC treated with first-line ICI-based combinations. Immunohistochemistry assessed ABCA1 and ABCG1 expression. Baseline data included serum lipids, albumin, CONUT score, neutrophil-to-lymphocyte ratio (NLR), and nephrectomy status. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier and Cox regression. Associations were tested with linear regression and Mann–Whitney tests. Results Among 86 patients (median follow-up: 30 months), median PFS was 25.6 months and OS was not reached. High ABCA1/ABCG1 expression correlated with shorter PFS and OS. Better outcomes were observed in patients with lower CONUT score, cholesterol ≥200 mg/dL, and triglycerides ≥150 mg/dL. Nephrectomy, performed in 59% of patients, was associated with significantly better survival and favorable baseline lipid and nutritional profiles. A combined nephrectomy-cholesterol score (0-2 points) stratified prognosis: higher scores predicted longer survival (Table 1). In multivariable analysis, both nephrectomy and high cholesterol were independently associated with reduced risk of progression and death. Conclusions In mRCC, high tumor expression of ABCA1/ABCG1 predicted poorer outcomes, while favorable metabolic and nutritional profiles and nephrectomy predicted improved survival. The nephrectomy-cholesterol score may serve as a prognostic tool and highlight the relevance of host metabolic status in ICI response.

Source: The Oncologist

DOI: 10.1093/oncolo/oyaf248.016